Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 for Recurrent Malignant Glioma
NCT01249105Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MK-2206 in malignant glioma (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Akt inhibition in tumor tissue at 2 years, MK-2206 levels in tumor tissue at 2 years and 1 more. Status: withdrawn.
02
Drugs
MK-2206
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT01249105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249105.